Officials have pursued these highly visible projects to impress their superiors and showcase their achievements, but in doing so they often take away resources from less glamorous but more effective ...
Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy. In this study, R, a bispecific checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results